Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Inoue K, Qin Y, Xia Y, Han J, Yuan R, Sun J, et al. Bone marrow Adipoq-lineage progenitors are a major cellular source of M-CSF that dominates bone marrow macrophage development, osteoclastogenesis, and bone mass. Elife. 2023;12.

Karafin MS, DeSimone RA, Dvorak J, Metcalf RA, Pagano MB, Park YA, et al. Antibody Titers in Transfusion Medicine: A Critical Reevaluation of Testing Accuracy, Reliability, and Clinical Use. Arch Pathol Lab Med. 2023;147(12):1351-1359.

Forlenza CJ, Chadburn A, Giulino-Roth L. Primary Mediastinal B-Cell Lymphoma in Children and Young Adults. J Natl Compr Canc Netw. 2023;21(3):323-330.

Nishida J, Cristea S, Bodapati S, Puleo J, Bai G, Patel A, et al. Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression. Proc Natl Acad Sci U S A. 2023;120(49):e2316763120.

Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo M-, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82(10):1258-1270.

Khan I, Wu S, Hudson A, Hughes C, Stryjniak G, Westblade LF, et al. A Distinct Nasal Microbiota Signature in Peritoneal Dialysis Patients. medRxiv. 2023.

Sud K, Narula N, Aikawa E, Arbustini E, Pibarot P, Merlini G, et al. The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis. Nat Rev Cardiol. 2023;20(6):418-428.

Oh W-, Yang Y-, Xie J, Ma H, Kim J-, Park K-, et al. WNT-modulating gene silencers as a gene therapy for osteoporosis, bone fracture, and critical-sized bone defects. Mol Ther. 2023;31(2):435-453.

Liu A, Kremyanskaya M, Mehrazin R, Si Q, Robinson BD, Cushing MM, et al. Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis. Am J Hematol. 2023;98(11):1808-1813.

Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2023;15:17588359231156147.